Alex B Blair1, Lauren M Rosati2, Neda Rezaee1, Georgios Gemenetzis1, Lei Zheng3, Ralph H Hruban4, John L Cameron1, Matthew J Weiss1, Christopher L Wolfgang1, Joseph M Herman5, Jin He6. 1. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA. 2. The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA. 3. The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA. 4. The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA. 5. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA; The Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA; The Sol Goldman Pancreatic Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA. Electronic address: jhe11@jhmi.edu.
Abstract
BACKGROUND: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy. METHODS: Patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses. RESULTS: A total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P = .017) and require a vascular resection (54% vs 37%, P = .027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P < .001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P = .471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group. CONCLUSION: Compared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.
BACKGROUND: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy. METHODS: Patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses. RESULTS: A total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P = .017) and require a vascular resection (54% vs 37%, P = .027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P < .001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P = .471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group. CONCLUSION: Compared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo Journal: Ann Surg Date: 2015-01 Impact factor: 12.969
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-05 Impact factor: 7.038
Authors: Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem Journal: Ann Surg Date: 2014-08 Impact factor: 12.969
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Malolan S Rajagopalan; Dwight E Heron; Rodney E Wegner; Herbert J Zeh; Nathan Bahary; Alyssa M Krasinskas; Barry Lembersky; Randall Brand; A James Moser; Annette E Quinn; Steven A Burton Journal: Radiat Oncol Date: 2013-10-31 Impact factor: 3.481
Authors: Thomas Hank; Marta Sandini; Cristina R Ferrone; Clifton Rodrigues; Maximilian Weniger; Motaz Qadan; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-Del Castillo Journal: JAMA Surg Date: 2019-10-01 Impact factor: 14.766
Authors: Shalini Moningi; Joseph Abi Jaoude; Ramez Kouzy; Daniel Lin; Nicholas D Nguyen; Carolina J Garcia Garcia; Jae L Phan; Santiago Avila; Daniel Smani; Irina M Cazacu; Ben S Singh; Grace L Smith; Emma B Holliday; Eugene J Koay; Prajnan Das; Manoop S Bhutani; Joseph M Herman; Bruce D Minsky; Albert C Koong; Cullen M Taniguchi Journal: Adv Radiat Oncol Date: 2020-11-23
Authors: Logan R McNeil; Alex B Blair; Robert W Krell; Chunmeng Zhang; Aslam Ejaz; Vincent P Groot; Georgios Gemenetzis; James C Padussis; Massimo Falconi; Christopher L Wolfgang; Matthew J Weiss; Chandrakanth Are; Jin He; Bradley N Reames Journal: Surg Open Sci Date: 2022-08-06
Authors: Abhinav V Reddy; Shuchi Sehgal; Colin S Hill; Lei Zheng; Jin He; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: Curr Oncol Date: 2022-01-11 Impact factor: 3.677